Abeona Therapeutics Inc. (ABEO)
USD 4.43
(-1.99%)
USD 4.43
(-1.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -54.18 Million USD | -70.35% |
| 2022 | -31.8 Million USD | 64.1% |
| 2021 | -88.6 Million USD | -0.29% |
| 2020 | -88.34 Million USD | -15.21% |
| 2019 | -76.68 Million USD | -35.31% |
| 2018 | -56.67 Million USD | -107.44% |
| 2017 | -27.31 Million USD | -24.9% |
| 2016 | -21.87 Million USD | -50.58% |
| 2015 | -14.52 Million USD | 45.75% |
| 2014 | -26.77 Million USD | -701.89% |
| 2013 | 4.44 Million USD | 142.24% |
| 2012 | -10.53 Million USD | -315.96% |
| 2011 | -2.53 Million USD | 66.41% |
| 2010 | -7.53 Million USD | 56.53% |
| 2009 | -17.34 Million USD | -0.73% |
| 2008 | -17.21 Million USD | 21.23% |
| 2007 | -21.85 Million USD | -69.77% |
| 2006 | -12.87 Million USD | -657.29% |
| 2005 | -1.7 Million USD | 83.4% |
| 2004 | -10.23 Million USD | -47.63% |
| 2003 | -6.93 Million USD | 26.1% |
| 2002 | -9.38 Million USD | -55.7% |
| 2001 | -6.02 Million USD | -11.04% |
| 2000 | -5.42 Million USD | -64.09% |
| 1999 | -3.3 Million USD | 2.71% |
| 1998 | -3.4 Million USD | 23.44% |
| 1997 | -4.44 Million USD | 61.25% |
| 1996 | -11.46 Million USD | -3461.29% |
| 1995 | 341 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 7.4 Million USD | 123.45% |
| 2024 Q1 | -31.57 Million USD | -90.33% |
| 2023 Q2 | -16.65 Million USD | -82.87% |
| 2023 Q1 | -9.1 Million USD | -241.96% |
| 2023 FY | -54.18 Million USD | -70.35% |
| 2023 Q4 | -16.59 Million USD | -40.17% |
| 2023 Q3 | -11.83 Million USD | 28.93% |
| 2022 FY | -31.8 Million USD | 64.1% |
| 2022 Q1 | -20.99 Million USD | 55.04% |
| 2022 Q2 | -7.12 Million USD | 66.07% |
| 2022 Q3 | -9.48 Million USD | -33.16% |
| 2022 Q4 | 6.41 Million USD | 167.64% |
| 2021 Q2 | -15.2 Million USD | 4.97% |
| 2021 Q1 | -16 Million USD | -1.1% |
| 2021 FY | -88.6 Million USD | -0.29% |
| 2021 Q4 | -46.68 Million USD | -562.73% |
| 2021 Q3 | -7.04 Million USD | 53.68% |
| 2020 Q3 | -7.23 Million USD | 44.37% |
| 2020 Q4 | -15.82 Million USD | -118.71% |
| 2020 Q1 | -48.15 Million USD | -193.1% |
| 2020 Q2 | -13.01 Million USD | 72.99% |
| 2020 FY | -88.34 Million USD | -15.21% |
| 2019 Q1 | -18.55 Million USD | 7.64% |
| 2019 FY | -76.68 Million USD | -35.31% |
| 2019 Q4 | -16.43 Million USD | 5.42% |
| 2019 Q3 | -17.37 Million USD | 27.39% |
| 2019 Q2 | -23.92 Million USD | -28.94% |
| 2018 Q1 | -8.46 Million USD | -0.15% |
| 2018 Q3 | -16.41 Million USD | -40.33% |
| 2018 Q4 | -20.08 Million USD | -22.35% |
| 2018 FY | -56.67 Million USD | -107.44% |
| 2018 Q2 | -11.7 Million USD | -38.25% |
| 2017 Q3 | -5.34 Million USD | 35.46% |
| 2017 FY | -27.31 Million USD | -24.9% |
| 2017 Q1 | -5.24 Million USD | 25.06% |
| 2017 Q2 | -8.27 Million USD | -57.79% |
| 2017 Q4 | -8.45 Million USD | -58.15% |
| 2016 Q1 | -5.54 Million USD | -136.92% |
| 2016 Q3 | -2.62 Million USD | 60.85% |
| 2016 Q2 | -6.7 Million USD | -20.91% |
| 2016 Q4 | -7 Million USD | -166.84% |
| 2016 FY | -21.87 Million USD | -50.58% |
| 2015 Q1 | -2 Million USD | 83.25% |
| 2015 Q3 | -6.07 Million USD | -47.65% |
| 2015 Q4 | -2.34 Million USD | 61.47% |
| 2015 FY | -14.52 Million USD | 45.75% |
| 2015 Q2 | -4.11 Million USD | -105.65% |
| 2014 Q3 | -1.46 Million USD | 88.25% |
| 2014 Q4 | -11.94 Million USD | -713.0% |
| 2014 FY | -26.77 Million USD | -701.89% |
| 2014 Q1 | -859 Thousand USD | 20.09% |
| 2014 Q2 | -12.5 Million USD | -1356.0% |
| 2013 Q1 | 4.08 Million USD | -79.42% |
| 2013 FY | 4.44 Million USD | 142.24% |
| 2013 Q4 | -1.07 Million USD | -584.71% |
| 2013 Q3 | -157 Thousand USD | -109.81% |
| 2013 Q2 | 1.6 Million USD | -60.79% |
| 2012 Q4 | 19.82 Million USD | 233.36% |
| 2012 Q3 | -14.86 Million USD | -40.25% |
| 2012 FY | -10.53 Million USD | -315.96% |
| 2012 Q2 | -10.6 Million USD | -116.68% |
| 2012 Q1 | -4.89 Million USD | -1840.93% |
| 2011 Q2 | -1.26 Million USD | 33.44% |
| 2011 Q4 | 281 Thousand USD | -19.71% |
| 2011 FY | -2.53 Million USD | 66.41% |
| 2011 Q1 | -1.89 Million USD | -182.46% |
| 2011 Q3 | 350 Thousand USD | 127.69% |
| 2010 Q4 | 2.3 Million USD | 118.11% |
| 2010 FY | -7.53 Million USD | 56.53% |
| 2010 Q3 | -12.71 Million USD | -810.56% |
| 2010 Q2 | 1.79 Million USD | 64.37% |
| 2010 Q1 | 1.08 Million USD | 112.14% |
| 2009 Q4 | -8.97 Million USD | -120.39% |
| 2009 FY | -17.34 Million USD | -0.73% |
| 2009 Q1 | -2.08 Million USD | -32.97% |
| 2009 Q3 | -4.07 Million USD | -84.38% |
| 2009 Q2 | -2.2 Million USD | -5.7% |
| 2008 Q4 | -1.57 Million USD | 44.01% |
| 2008 FY | -17.21 Million USD | 21.23% |
| 2008 Q1 | -10.59 Million USD | 22.45% |
| 2008 Q2 | -2.24 Million USD | 78.83% |
| 2008 Q3 | -2.8 Million USD | -25.1% |
| 2007 FY | -21.85 Million USD | -69.77% |
| 2007 Q4 | -13.66 Million USD | -598.16% |
| 2007 Q2 | -2.1 Million USD | 48.9% |
| 2007 Q1 | -4.12 Million USD | -54.45% |
| 2007 Q3 | -1.95 Million USD | 7.21% |
| 2006 Q3 | -2.01 Million USD | 39.51% |
| 2006 Q2 | -3.33 Million USD | 31.4% |
| 2006 Q1 | -4.85 Million USD | -173.9% |
| 2006 FY | -12.87 Million USD | -657.29% |
| 2006 Q4 | -2.67 Million USD | -32.61% |
| 2005 Q1 | -2.42 Million USD | 16.66% |
| 2005 Q3 | -2.06 Million USD | 45.51% |
| 2005 Q2 | -3.78 Million USD | -56.32% |
| 2005 Q4 | 6.57 Million USD | 418.52% |
| 2005 FY | -1.7 Million USD | 83.4% |
| 2004 Q4 | -2.9 Million USD | -19.69% |
| 2004 FY | -10.23 Million USD | -47.63% |
| 2004 Q2 | -2.55 Million USD | -8.59% |
| 2004 Q1 | -2.35 Million USD | 10.74% |
| 2004 Q3 | -2.42 Million USD | 4.9% |
| 2003 Q1 | -2.41 Million USD | -2.51% |
| 2003 FY | -6.93 Million USD | 26.1% |
| 2003 Q4 | -2.63 Million USD | -19.4% |
| 2003 Q2 | 316 Thousand USD | 113.11% |
| 2003 Q3 | -2.2 Million USD | -798.1% |
| 2002 Q3 | -2.85 Million USD | -23.83% |
| 2002 Q4 | -2.35 Million USD | 17.7% |
| 2002 Q1 | -1.86 Million USD | -16.99% |
| 2002 Q2 | -2.3 Million USD | -23.69% |
| 2002 FY | -9.38 Million USD | -55.7% |
| 2001 Q4 | -1.59 Million USD | 8.54% |
| 2001 FY | -6.02 Million USD | -11.04% |
| 2001 Q3 | -1.74 Million USD | -14.96% |
| 2001 Q2 | -1.51 Million USD | -29.55% |
| 2001 Q1 | -1.17 Million USD | 26.44% |
| 2000 Q2 | -1.44 Million USD | -33.89% |
| 2000 Q3 | -1.31 Million USD | 9.41% |
| 2000 Q4 | -1.59 Million USD | -21.53% |
| 2000 FY | -5.42 Million USD | -64.09% |
| 2000 Q1 | -1.08 Million USD | -18.68% |
| 1999 Q4 | -910 Thousand USD | -27.99% |
| 1999 Q1 | -799 Thousand USD | -5.13% |
| 1999 FY | -3.3 Million USD | 2.71% |
| 1999 Q3 | -711 Thousand USD | 19.93% |
| 1999 Q2 | -888 Thousand USD | -11.14% |
| 1998 Q4 | -760 Thousand USD | 6.17% |
| 1998 Q1 | -900 Thousand USD | 45.45% |
| 1998 Q2 | -930 Thousand USD | -3.33% |
| 1998 Q3 | -810 Thousand USD | 12.9% |
| 1998 FY | -3.4 Million USD | 23.44% |
| 1997 Q3 | -1.11 Million USD | -21.98% |
| 1997 FY | -4.44 Million USD | 61.25% |
| 1997 Q1 | -760 Thousand USD | 40.16% |
| 1997 Q4 | -1.65 Million USD | -48.65% |
| 1997 Q2 | -910 Thousand USD | -19.74% |
| 1996 Q3 | -870 Thousand USD | -38.1% |
| 1996 Q1 | -8.69 Million USD | -1279.37% |
| 1996 Q2 | -630 Thousand USD | 92.75% |
| 1996 FY | -11.46 Million USD | -3461.29% |
| 1996 Q4 | -1.27 Million USD | -45.98% |
| 1995 FY | 341 Thousand USD | 0.0% |
| 1995 Q4 | -630 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 62.986% |
| Alkermes plc | 355.75 Million USD | 115.232% |
| Agenus Inc. | -245.76 Million USD | 77.951% |
| Aptorum Group Limited | -2.82 Million USD | -1818.399% |
| Ardelyx, Inc. | -66.06 Million USD | 17.98% |
| Dyadic International, Inc. | -6.79 Million USD | -697.415% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -5689.316% |
| Lantern Pharma Inc. | -15.96 Million USD | -239.491% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | -184.767% |
| Novavax, Inc. | -545.06 Million USD | 90.058% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 7.042% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 26.565% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | -192.18% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -442.64% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 8.129% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 85.497% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -122.636% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | -45.121% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 67.074% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 26.121% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -167.054% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 12.958% |
| Clearside Biomedical, Inc. | -32.48 Million USD | -66.809% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 59.101% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 87.691% |
| AlloVir, Inc. | -190.41 Million USD | 71.543% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 73.602% |
| VYNE Therapeutics Inc. | -28.45 Million USD | -90.454% |
| Bicycle Therapeutics plc | -180.66 Million USD | 70.006% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 69.736% |
| ChromaDex Corporation | -4.93 Million USD | -997.367% |
| Chimerix, Inc. | -82.09 Million USD | 33.994% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -21.489% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 46.911% |
| CRISPR Therapeutics AG | -153.61 Million USD | 64.724% |
| Precision BioSciences, Inc. | -61.31 Million USD | 11.629% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 66.328% |
| Fortress Biotech, Inc. | -60.63 Million USD | 10.635% |
| Fortress Biotech, Inc. | -60.63 Million USD | 10.635% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 33.577% |
| ImmuCell Corporation | -5.77 Million USD | -838.386% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 52.029% |
| Immix Biopharma, Inc. | -15.42 Million USD | -251.276% |
| Incyte Corporation | 597.59 Million USD | 109.068% |
| Innoviva, Inc. | 179.72 Million USD | 130.151% |
| IO Biotech, Inc. | -86.08 Million USD | 37.051% |
| Jaguar Health, Inc. | -41.3 Million USD | -31.206% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 64.581% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 203.9% |
| ContextLogic Inc. | -317 Million USD | 82.906% |
| MiMedx Group, Inc. | 67.43 Million USD | 180.351% |
| MEI Pharma, Inc. | 17.77 Million USD | 404.804% |
| NextCure, Inc. | -62.72 Million USD | 13.607% |
| Onconetix, Inc. | -37.4 Million USD | -44.85% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | -37.258% |
| Opthea Limited | -220.24 Million USD | 75.396% |
| Psyence Biomedical Ltd. | -51.15 Million USD | -5.921% |
| Vaxcyte, Inc. | -402.26 Million USD | 86.529% |
| PDS Biotechnology Corporation | -42.94 Million USD | -26.188% |
| Precigen, Inc. | -95.9 Million USD | 43.498% |
| Pharming Group N.V. | -10.54 Million USD | -413.728% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 73.12% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | -120.788% |
| PureTech Health plc | -65.69 Million USD | 17.518% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | -115.966% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 74.466% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -122.636% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 78.983% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | -98.943% |
| Acelyrin, Inc. | -381.64 Million USD | 85.801% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -431928.536% |
| Summit Therapeutics Inc. | -614.92 Million USD | 91.188% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | -58.904% |
| Senti Biosciences, Inc. | -92.91 Million USD | 41.683% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 48.244% |
| Elevation Oncology, Inc. | -45.7 Million USD | -18.563% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | -54.206% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | -314.539% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -710.591% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | -84.551% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -537.431% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 5.781% |
| Seer, Inc. | -86.27 Million USD | 37.193% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 19.116% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 17.604% |
| ESSA Pharma Inc. | -26.58 Million USD | -103.85% |
| GlycoMimetics, Inc. | -36.89 Million USD | -46.853% |
| GT Biopharma, Inc. | -7.59 Million USD | -613.282% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 77.549% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | -4.358% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 175.883% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 0.43% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | -10.318% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -444.726% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 90.541% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -1410.256% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -6.13% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 77.936% |
| Aptose Biosciences Inc. | -51.2 Million USD | -5.821% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 44.874% |
| Soligenix, Inc. | -6.14 Million USD | -782.436% |
| Century Therapeutics, Inc. | -136.67 Million USD | 60.352% |
| Kura Oncology, Inc. | -152.63 Million USD | 64.497% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 39.263% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -414.215% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 9682.825% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -9423.374% |
| Autolus Therapeutics plc | -208.38 Million USD | 73.996% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 24.632% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 23.458% |
| Eterna Therapeutics Inc. | -21.66 Million USD | -150.083% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 75.943% |
| GRI Bio, Inc. | -13.03 Million USD | -315.648% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -1210.605% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 56.33% |
| IGM Biosciences, Inc. | -246.41 Million USD | 78.01% |
| INmune Bio, Inc. | -30 Million USD | -80.579% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 50.987% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -28.426% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -239.489% |
| Entero Therapeutics, Inc. | -15.79 Million USD | -243.071% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 9.21% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 46.437% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 80.376% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 77.222% |
| Verastem, Inc. | -87.36 Million USD | 37.977% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 66.413% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 53.55% |
| Histogen Inc. | -10.62 Million USD | -410.197% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | -279.288% |
| Surrozen, Inc. | -43.04 Million USD | -25.896% |
| Organovo Holdings, Inc. | -14.67 Million USD | -269.355% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -965.219% |
| Ovid Therapeutics Inc. | -52.33 Million USD | -3.533% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -114.496% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | -101.158% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -548.408% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 64.134% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | -10.755% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | -82.298% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -420.153% |
| Apollomics, Inc. | -172.6 Million USD | 68.605% |
| Amarin Corporation plc | -59.11 Million USD | 8.33% |
| Mesoblast Limited | -87.95 Million USD | 38.392% |
| Turnstone Biologics Corp. | -55.2 Million USD | 1.833% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 63.128% |
| Synaptogenix, Inc. | -6.03 Million USD | -797.375% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | -234.329% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 30.546% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1030.927% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -544.927% |
| Exelixis, Inc. | 207.76 Million USD | 126.081% |
| Better Therapeutics, Inc. | -39.76 Million USD | -36.288% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 62.356% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 89.749% |
| NLS Pharmaceutics AG | -12.17 Million USD | -345.185% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -595.191% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -76.227% |
| Gritstone bio, Inc. | -138.49 Million USD | 60.872% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 15.942% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -1254.717% |
| Avid Bioservices, Inc. | -140.75 Million USD | 61.501% |
| Insmed Incorporated | -749.56 Million USD | 92.771% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | -256.746% |
| MediWound Ltd. | -6.71 Million USD | -706.849% |
| OmniAb, Inc. | -50.61 Million USD | -7.051% |
| Alector, Inc. | -130.39 Million USD | 58.442% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 52.351% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | -4.515% |
| Zai Lab Limited | -334.62 Million USD | 83.806% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 83.275% |
| Aura Biosciences, Inc. | -76.4 Million USD | 29.081% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 76.905% |
| Immunic, Inc. | -93.61 Million USD | 42.114% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 60.125% |
| Veracyte, Inc. | -74.4 Million USD | 27.171% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -605.982% |
| FibroGen, Inc. | -284.23 Million USD | 80.935% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -106.572% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -673.905% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | -187.734% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 113.063% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | -140.248% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 209.98% |
| TG Therapeutics, Inc. | 12.67 Million USD | 527.62% |
| Galecto, Inc. | -38.34 Million USD | -41.302% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -187.226% |
| Fortrea Holdings Inc. | -3.4 Million USD | -1493.765% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 57.212% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | -211.229% |
| XBiotech Inc. | -24.55 Million USD | -120.662% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 15.942% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 13.548% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 44.945% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | -152.896% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 1.821% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 91.068% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 20.609% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -95076.871% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 76.08% |
| Gain Therapeutics, Inc. | -22.26 Million USD | -143.35% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 75.337% |
| NexImmune, Inc. | -32.34 Million USD | -67.534% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -925.012% |
| Marker Therapeutics, Inc. | -14.04 Million USD | -285.792% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.371% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | -123.723% |
| Scopus BioPharma Inc. | -11.6 Million USD | -366.743% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 53.605% |
| Ainos, Inc. | -13.77 Million USD | -293.506% |
| Pluri Inc. | -20.88 Million USD | -159.422% |
| Prothena Corporation plc | -147.02 Million USD | 63.144% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 52.413% |
| Celularity Inc. | -196.29 Million USD | 72.395% |
| Rallybio Corporation | -74.56 Million USD | 27.327% |
| Cue Biopharma, Inc. | -50.73 Million USD | -6.81% |
| MeiraGTx Holdings plc | -84.02 Million USD | 35.511% |
| Omeros Corporation | -117.81 Million USD | 54.005% |
| Humacyte, Inc. | -110.77 Million USD | 51.083% |
| Immunocore Holdings plc | -55.28 Million USD | 1.988% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | -201.312% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | -136.309% |
| Blueprint Medicines Corporation | -506.98 Million USD | 89.312% |
| CalciMedica, Inc. | -34.35 Million USD | -57.72% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 19.929% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 61.679% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 67.315% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 80.87% |
| Pulmatrix, Inc. | -14.12 Million USD | -283.741% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | -53.965% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 34.427% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 88.739% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 48.329% |
| Cytokinetics, Incorporated | -526.24 Million USD | 89.703% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -50.251% |
| Nutriband Inc. | -5.48 Million USD | -887.874% |
| Protara Therapeutics, Inc. | -40.42 Million USD | -34.062% |
| Vor Biopharma Inc. | -117.86 Million USD | 54.025% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 101.246% |
| Evogene Ltd. | -23.87 Million USD | -126.927% |
| ProKidney Corp. | -35.46 Million USD | -52.78% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 54.754% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -590.699% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 91.575% |
| CorMedix Inc. | -46.33 Million USD | -16.938% |
| BioLineRx Ltd. | -60.61 Million USD | 10.602% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 46.741% |
| Galectin Therapeutics Inc. | -41.06 Million USD | -31.953% |
| Atai Life Sciences N.V. | -40.22 Million USD | -34.716% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 32.811% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 28.248% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 81.455% |
| Sagimet Biosciences Inc. | -27.87 Million USD | -94.389% |
| MediciNova, Inc. | -8.57 Million USD | -532.187% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 56.044% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -546.879% |
| GeoVax Labs, Inc. | -25.96 Million USD | -108.682% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 77.35% |
| Biomea Fusion, Inc. | -117.25 Million USD | 53.786% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 91.352% |
| Mereo BioPharma Group plc | -29.46 Million USD | -83.9% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 64.62% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 74.117% |
| Absci Corporation | -110.56 Million USD | 50.99% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -79.728% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 46.262% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 77.033% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 484.749% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 71.918% |
| Allakos Inc. | -185.7 Million USD | 70.82% |
| Imunon, Inc. | -19.51 Million USD | -177.674% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 44.328% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 151.053% |
| BioAtla, Inc. | -123.46 Million USD | 56.11% |
| NLS Pharmaceutics AG | -12.17 Million USD | -345.185% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -237.032% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 83.442% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | -46.656% |
| XOMA Corporation | -40.83 Million USD | -32.713% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 46.807% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 54.277% |
| aTyr Pharma, Inc. | -50.38 Million USD | -7.539% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 38.197% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 64.293% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 77.206% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | -54.298% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -569.654% |
| Akari Therapeutics, Plc | -10 Million USD | -441.447% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -80387.189% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 119.243% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -713.036% |
| UroGen Pharma Ltd. | -102.24 Million USD | 47.001% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 49.259% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -596.756% |
| Orgenesis Inc. | -55.36 Million USD | 2.119% |
| Entera Bio Ltd. | -8.88 Million USD | -509.607% |
| GH Research PLC | -35.58 Million USD | -52.269% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | -160.019% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 29.979% |
| Xencor, Inc. | -126.08 Million USD | 57.023% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -1338.988% |
| Replimune Group, Inc. | -215.79 Million USD | 74.889% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | -154.804% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 2259.745% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -713.036% |
| Portage Biotech Inc. | -75.33 Million USD | 28.074% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -546.879% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 43.937% |
| OncoCyte Corporation | -27.78 Million USD | -95.054% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | -303.869% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | -387.236% |
| Purple Biotech Ltd. | -19.88 Million USD | -172.575% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -672.019% |
| scPharmaceuticals Inc. | -54.81 Million USD | 1.135% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | -209.537% |
| HilleVax, Inc. | -123.56 Million USD | 56.147% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -436.143% |
| Tharimmune, Inc. | -9.31 Million USD | -481.473% |
| Genprex, Inc. | -30.86 Million USD | -75.59% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 77.032% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | -80.062% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -2940.853% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -923.184% |
| OKYO Pharma Limited | -16.82 Thousand USD | -321959.545% |
| Savara Inc. | -54.69 Million USD | 0.932% |
| Curis, Inc. | -47.41 Million USD | -14.289% |
| Daré Bioscience, Inc. | -30.16 Million USD | -79.66% |
| Carmell Therapeutics Corporation | -15.44 Million USD | -250.843% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -873.029% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | -81.747% |
| BeiGene, Ltd. | -881.7 Million USD | 93.854% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -154.475% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 87.582% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 31.369% |
| Erasca, Inc. | -125.04 Million USD | 56.664% |
| bluebird bio, Inc. | -211.91 Million USD | 74.429% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -983.652% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 132.323% |
| DBV Technologies S.A. | -72.72 Million USD | 25.49% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -983.652% |
| Moderna, Inc. | -4.71 Billion USD | 98.85% |
| Vincerx Pharma, Inc. | -40.15 Million USD | -34.94% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -851.668% |
| Molecular Templates, Inc. | -8.12 Million USD | -567.011% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 10.267% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 51.357% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 59.965% |
| Spruce Biosciences, Inc. | -47.91 Million USD | -13.082% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 61.685% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 71.837% |
| MacroGenics, Inc. | -9.05 Million USD | -498.234% |
| RenovoRx, Inc. | -10.23 Million USD | -429.593% |
| Adicet Bio, Inc. | -142.65 Million USD | 62.015% |
| Prime Medicine, Inc. | -198.13 Million USD | 72.651% |
| Aditxt, Inc. | -32.38 Million USD | -67.346% |
| Adagene Inc. | -18.94 Million USD | -186.007% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -641.111% |
| Quantum-Si incorporated | -95.96 Million USD | 43.531% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 54.475% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -271.717% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 140.949% |
| SciSparc Ltd. | -5.12 Million USD | -957.946% |
| Vericel Corporation | -3.18 Million USD | -1602.954% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -44961.287% |
| Minerva Neurosciences, Inc. | -30 Million USD | -80.594% |
| Generation Bio Co. | -126.61 Million USD | 57.202% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 25.659% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 34.271% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 79.329% |
| Invivyd, Inc. | -198.64 Million USD | 72.721% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 84.154% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -523.813% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 337.604% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -448.795% |
| 2seventy bio, Inc. | -217.57 Million USD | 75.094% |
| ADMA Biologics, Inc. | -28.23 Million USD | -91.891% |
| Clene Inc. | -49.5 Million USD | -9.462% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | -143.131% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | -9.617% |
| GeoVax Labs, Inc. | -25.96 Million USD | -108.682% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 83.483% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | -66.512% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 338.504% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 45.149% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 27.512% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 66.302% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 91.19% |
| Evaxion Biotech A/S | -22.12 Million USD | -144.918% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 32.882% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 72.915% |
| Trevena, Inc. | -40.28 Million USD | -34.498% |
| Surrozen, Inc. | -43.04 Million USD | -25.896% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 21.619% |
| Cingulate Inc. | -23.53 Million USD | -130.245% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -683.97% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -35.946% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -602.766% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 39.931% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 11.582% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 8.932% |
| Clearmind Medicine Inc. | -11.95 Million USD | -353.265% |
| Kronos Bio, Inc. | -112.67 Million USD | 51.907% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 21.69% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -2136457.016% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 36.914% |
| Statera Biopharma, Inc. | -174.4 Million USD | 68.93% |
| ImmunityBio, Inc. | -583.19 Million USD | 90.708% |
| Korro Bio, Inc. | -81.17 Million USD | 33.243% |
| Kineta, Inc. | -14.09 Million USD | -284.339% |
| BioVie Inc. | -32.12 Million USD | -68.702% |
| Codexis, Inc. | -76.24 Million USD | 28.924% |
| Celularity Inc. | -196.29 Million USD | 72.395% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 74.741% |
| Celcuity Inc. | -63.77 Million USD | 15.038% |
| Virax Biolabs Group Limited | -6.73 Million USD | -704.748% |
| Cibus, Inc. | -267.62 Million USD | 79.752% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | -34.375% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -51.317% |
| IN8bio, Inc. | -30 Million USD | -80.585% |
| Kodiak Sciences Inc. | -260.49 Million USD | 79.198% |
| Annexon, Inc. | -134.23 Million USD | 59.633% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 53.751% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 11.498% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | -71.785% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 85.206% |
| Eyenovia, Inc. | -27.26 Million USD | -98.774% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 350.975% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -10028.598% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 29.077% |
| Arcellx, Inc. | -70.69 Million USD | 23.344% |
| Cardiff Oncology, Inc. | -41.44 Million USD | -30.759% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 59.506% |
| Regulus Therapeutics Inc. | -30.03 Million USD | -80.404% |
| Moolec Science SA | -51.78 Million USD | -4.633% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | -3.469% |
| Geron Corporation | -184.12 Million USD | 70.57% |
| LAVA Therapeutics N.V. | -41.97 Million USD | -29.099% |
| Royalty Pharma plc | 1.13 Billion USD | 104.775% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 60.143% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -509.415% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | -155.084% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 68.435% |
| Humacyte, Inc. | -110.77 Million USD | 51.083% |
| Structure Therapeutics Inc. | -89.62 Million USD | 39.536% |
| 89bio, Inc. | -142.18 Million USD | 61.89% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 21.421% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -422.193% |
| Genelux Corporation | -28.29 Million USD | -91.497% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | -86.437% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 69.406% |
| Notable Labs, Ltd. | -11.26 Million USD | -381.072% |
| Liquidia Corporation | -78.5 Million USD | 30.972% |
| Mustang Bio, Inc. | -51.6 Million USD | -5.011% |
| Immunovant, Inc. | -259.33 Million USD | 79.105% |
| Quantum-Si incorporated | -95.96 Million USD | 43.531% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 25.616% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | -179.593% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 43.548% |
| Acasti Pharma Inc. | -12.85 Million USD | -321.598% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | -141.287% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -239.489% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 70.291% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -1159.742% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | -334.547% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | -83.744% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | -38.986% |
| PepGen Inc. | -78.62 Million USD | 31.081% |
| Moleculin Biotech, Inc. | -29.76 Million USD | -82.028% |
| United Therapeutics Corporation | 984.8 Million USD | 105.502% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | -143.432% |
| Solid Biosciences Inc. | -96.01 Million USD | 43.563% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1030.927% |
| Immuneering Corporation | -53.47 Million USD | -1.34% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -965.219% |
| Silo Pharma, Inc. | -3.7 Million USD | -1364.27% |
| Belite Bio, Inc | -31.63 Million USD | -71.308% |
| XOMA Corporation | -40.83 Million USD | -32.713% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 0.326% |
| Bionomics Limited | -15.49 Billion USD | 99.65% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 35.479% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -85.849% |
| uniQure N.V. | -308.47 Million USD | 82.434% |
| Cassava Sciences, Inc. | -97.21 Million USD | 44.261% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -641.111% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 56.098% |
| Forte Biosciences, Inc. | -31.47 Million USD | -72.157% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -560.692% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | -86.418% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -10028.598% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -106.572% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | -228.711% |
| Altimmune, Inc. | -88.44 Million USD | 38.734% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 64.252% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -85.849% |
| Compugen Ltd. | -18.75 Million USD | -188.941% |
| Peak Bio, Inc. | -1259.26 USD | -4303062.175% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | -17.675% |
| Benitec Biopharma Inc. | -21.75 Million USD | -149.129% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 84.005% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 34.677% |
| Zura Bio Limited | -60.36 Million USD | 10.225% |
| PolyPid Ltd. | -23.86 Million USD | -127.061% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | -244.444% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 34.677% |
| Instil Bio, Inc. | -156.08 Million USD | 65.283% |
| argenx SE | -295.05 Million USD | 81.634% |
| Immunome, Inc. | -106.8 Million USD | 49.265% |
| Compass Therapeutics, Inc. | -42.49 Million USD | -27.519% |
| Verona Pharma plc | -54.36 Million USD | 0.333% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 45.767% |
| Shattuck Labs, Inc. | -87.29 Million USD | 37.928% |
| CervoMed Inc. | -2.17 Million USD | -2394.989% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 56.528% |
| Plus Therapeutics, Inc. | -13.31 Million USD | -306.939% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | -24.413% |
| Moolec Science SA | -51.78 Million USD | -4.633% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -313275.238% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 59.896% |
| AnaptysBio, Inc. | -163.61 Million USD | 66.882% |
| Design Therapeutics, Inc. | -66.86 Million USD | 18.955% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 33.441% |
| NeurAxis, Inc. | -14.62 Million USD | -270.474% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | -43.044% |
| Lumos Pharma, Inc. | -34.03 Million USD | -59.217% |
| Achilles Therapeutics plc | -69.66 Million USD | 22.216% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 45.767% |
| 180 Life Sciences Corp. | -19.93 Million USD | -171.822% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 1900.99% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -2136457.016% |
| Nutriband Inc. | -5.48 Million USD | -887.874% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 46.187% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | -11.482% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 29.709% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | -59.517% |
| MoonLake Immunotherapeutics | -36 Million USD | -50.492% |
| Palisade Bio, Inc. | -12.3 Million USD | -340.553% |
| Tourmaline Bio, Inc. | -42.12 Million USD | -28.639% |
| Beam Therapeutics Inc. | -132.52 Million USD | 59.112% |
| Neurogene Inc. | -36.31 Million USD | -49.208% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 66.84% |
| AEON Biopharma, Inc. | -52.55 Million USD | -3.105% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 44.789% |
| Sesen Bio, Inc. | -19.88 Million USD | -172.521% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 24.302% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | -333.023% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 87.797% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 51.43% |
| Athira Pharma, Inc. | -117.67 Million USD | 53.95% |
| Vaccinex, Inc. | -20.25 Million USD | -167.582% |
| HCW Biologics Inc. | -24.99 Million USD | -116.802% |
| XOMA Corporation | -40.83 Million USD | -32.713% |
| Nektar Therapeutics | -276.05 Million USD | 80.371% |
| Arvinas, Inc. | -367.3 Million USD | 85.247% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -80387.189% |
| Merus N.V. | -154.93 Million USD | 65.026% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 44.381% |
| Quince Therapeutics, Inc. | -31.38 Million USD | -72.656% |
| Rezolute, Inc. | -68.45 Million USD | 20.846% |
| Clene Inc. | -49.5 Million USD | -9.462% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -251.335% |
| BeyondSpring Inc. | -21.02 Million USD | -157.719% |
| Synlogic, Inc. | -57.28 Million USD | 5.401% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | -355.323% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -400.536% |
| Peak Bio, Inc. | -1259.26 USD | -4303062.175% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | -45.012% |
| Krystal Biotech, Inc. | 10.93 Million USD | 595.682% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 62.133% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 83.332% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -1073.163% |
| MannKind Corporation | -11.93 Million USD | -353.912% |
| Ikena Oncology, Inc. | -68.16 Million USD | 20.506% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | -157.854% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 41.691% |
| Gossamer Bio, Inc. | -179.81 Million USD | 69.865% |
| CohBar, Inc. | -11.96 Million USD | -352.997% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | -110.129% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -79.728% |
| Legend Biotech Corporation | -518.25 Million USD | 89.544% |
| Mural Oncology plc | -207.44 Million USD | 73.879% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 56.34% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -196.276% |
| Disc Medicine, Inc. | -76.42 Million USD | 29.1% |
| Champions Oncology, Inc. | -7.27 Million USD | -644.75% |
| REGENXBIO Inc. | -263.49 Million USD | 79.435% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | -410.578% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -14.068% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | -42.662% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 45.9% |
| Vaxart, Inc. | -82.46 Million USD | 34.29% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 16335.472% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | -44.338% |
| Cellectis S.A. | -101.05 Million USD | 46.38% |
| Longeveron Inc. | -21.41 Million USD | -153.061% |
| Repare Therapeutics Inc. | -93.79 Million USD | 42.228% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 89.89% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 23.86% |
| Revolution Medicines, Inc. | -436.36 Million USD | 87.582% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -724.654% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | -75.798% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 21.844% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 16.289% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -452.319% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.497% |
| Denali Therapeutics Inc. | -145.22 Million USD | 62.687% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -44961.287% |
| Veru Inc. | -93.15 Million USD | 41.829% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | -100.481% |
| Cingulate Inc. | -23.53 Million USD | -130.245% |
| Passage Bio, Inc. | -102.06 Million USD | 46.907% |
| Context Therapeutics Inc. | -23.96 Million USD | -126.121% |
| Exicure, Inc. | -16.91 Million USD | -220.374% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 71.317% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | -43.491% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -732.723% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 70.658% |
| Nuvalent, Inc. | -126.21 Million USD | 57.068% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -415.308% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 37.628% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | -77.41% |
| OmniAb, Inc. | -50.61 Million USD | -7.051% |
| Anew Medical, Inc. | 1.34 Million USD | 4125.481% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | -237.725% |
| Lipocine Inc. | -16.35 Million USD | -231.383% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 18.384% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 14.899% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -28.426% |
| G1 Therapeutics, Inc. | -47.96 Million USD | -12.969% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | -173.249% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 89.993% |
| Ocugen, Inc. | -63.07 Million USD | 14.094% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 43.396% |
| Q32 Bio Inc. | -112.96 Million USD | 52.029% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | -215.193% |
| Alumis Inc. Common Stock | -154.99 Million USD | 65.038% |
| Equillium, Inc. | -13.33 Million USD | -306.359% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 10.234% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -578.381% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | -187.451% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 8.283% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 52.685% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -194.853% |
| Dominari Holdings Inc. | -22.88 Million USD | -136.815% |
| Edesa Biotech, Inc. | -8.37 Million USD | -547.066% |
| vTv Therapeutics Inc. | -20.25 Million USD | -167.595% |
| Bio-Techne Corporation | 168.1 Million USD | 132.235% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 84.61% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 142.054% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 55.522% |
| Candel Therapeutics, Inc. | -37.93 Million USD | -42.829% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 51.894% |
| Nkarta, Inc. | -117.5 Million USD | 53.883% |
| BioCardia, Inc. | -11.57 Million USD | -368.309% |
| Iterum Therapeutics plc | -38.37 Million USD | -41.221% |